$5.340
+0.010 (+0.19%)At close
IMA News
IMA Events
Selling Stockholders Plan to Sell 5.77M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.77M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
ImageneBio Files $200M Mixed Securities Shelf
ImageneBio files $200M mixed securities shelf
Imagene CEO Says Olevaprubart Poised to Become Leading OX40 Signal Blockade Program
"Imagene's olevaprubart is now primed to emerge as the leading OX40 signal blockade program. With our continued progress in advanced clinical development, our conviction remains strong," said Kristin Yarema, chief executive officer of Imagene. "Olevaprubart was engineered to be a genuinely differentiated medicine with the potential for strong, competitive efficacy and a favorable safety profile. This is what our Phase 2b ADAPTIVE study is designed to evaluate and we are very pleased with our progress. Atopic dermatitis and alopecia areata remain areas of significant unmet need, and, as we are following every new development in the field closely, none of it changes what we believe: that direct, T cell-targeted yet non-T cell depleting approaches like ours have the potential to provide durable, safe and strong benefit for patients. Our programs remain on track and we continue to advance as planned, including welcoming patients who have completed a year of treatment into our long-term extension study."
ImageneBio Appoints Matt Robbins as General Counsel
ImageneBio announced the appointment of Matt Robbins as general counsel, effective July 7. Robbins joins the clinical-stage biotechnology company from Bright Peak Therapeutics, where he served as general counsel. In his new role, Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, CEO of Imagene. "Matt's experience building a legal function inside a clinical-stage biotech company, combined with his years advising life science companies through public offerings and complex transactions, is a great fit for Imagene as we continue to advance and scale up our Phase 2 clinical programs in atopic dermatitis and alopecia areata. As we celebrate our one-year company anniversary later this month, we are entering an exciting new phase of growth with important milestones and data readouts on the horizon. Matt's leadership and expertise will be invaluable as we continue to grow, strengthen our organization, and execute on our strategic priorities."
Imagene Reports FY25 Revenue of $800K, IMG-007 Leading in Clinical Development
Reports FY25 revenue $800k vs $3.5M last year. "IMG-007 is now the leading receptor-targeting OX40 antagonist program in clinical development. Our approach is entirely unlike that of ADCC-enhanced anti-OX40 antibodies such as rocatinlimab: published data has shown rocatinlimab treatment causes deep depletion of T cells, while IMG-007 is a non-T cell depleting antibody. This is a fundamental, intentional, and critical difference in our molecule's design," commented Kristin Yarema, PhD, Chief Executive Officer of Imagene. "While the clinical profile of IMG-007 remains early, our safety database continues to grow and we have not seen any of the tolerability issues mechanistically linked to T cell depletion -- pyrexia, chills, ulcers -- nor have we seen any malignancies. This emerging clinical profile adds to the compelling, competitive efficacy we saw in our proof-of-concept studies in atopic dermatitis and alopecia areata. We are confident that ADAPTIVE, our Phase 2b dose-ranging study in AD, is robust and designed to well characterize IMG-007's efficacy, safety, and convenience for patients."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。